Beta Bionics, Inc.
https://www.betabionics.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Beta Bionics, Inc.
News We’re Watching: Apple/Masimo Patent Fight Update; Acutus Winds Down; Illumina Bails On Grail
Medtech Insight's News We're Watching highlights medtech industry developments that you may have missed over the last few weeks. In addition to the big news from Acutus, Apple, and Illumina, Masimo scored an important FDA clearance, Beta Bionics announced the US launch of its iLet bionic pancreas for Dexcom’s G7 CGM, and more.
Beta Bionics Secures $100M In Series D Funding To Expand Artificial Pancreas Tech
After receiving US FDA clearance in May, Beta Bionics secured $100m in financing which is expected to be used to commercialize its iLet Bionic Pancreas and “further develop and test the bi-hormonal bionic pancreas.”
Market Intel: Rivalry Among Insulin Pump Makers Heats Up With Expected Launches In 2021
The global insulin pump market is expected to see double-digit growth, reaching $5.1bn in 2024, with product launches expected by Medtronic, Insulet, Tandem and smaller players in 2021.
Tandem Wins FDA Clearance On First Stand-Alone Glycemic Controller
Tandem Diabetes Care received FDA clearance for its Control-IQ technology for use with Tandem's t:slim X2 insulin pump and Dexcom's G6 continuous glucose monitoring system, making it the first hybrid closed-loop system to deliver automatic correction boluses and adjust background insulin levels to help prevent high and low blood sugars.
Company Information
- Industry
- Biotechnology
- Medical Devices
-
Pharmaceuticals
- Drug Delivery
-
Medical Devices
- Monitoring Equipment & Devices
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice